Short Interest in Lonza Group Ag (OTCMKTS:LZAGY) Rises By 254.9%

Key Points

• Short interest in Lonza Group AG increased significantly by 254.9% in July, reaching a total of 29,100 shares.
• The company's stock price is trading around $69.65, with a 12 month low of $55.57 and a high of $73.29.
• Lonza Group recently increased its dividend to $0.1054 per share, marking a rise from the previous amount of $0.10.

Lonza Group Ag (OTCMKTS:LZAGY - ) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 29,100 shares, agrowthof254.9% from the June 30th total of 8,200 shares. Based on an average trading volume of 175,100 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 175,100 shares, the days-to-cover ratio is presently 0.2 days.

Lonza Group Stock Down 0.1%

LZAGY opened at $69.65 on Friday. Lonza Group has a 12 month low of $55.57 and a 12 month high of $73.29. The firm's fifty day simple moving average is $69.98 and its 200 day simple moving average is $66.96. The company has a quick ratio of 1.04, a current ratio of 1.52 and a debt-to-equity ratio of 0.45.

Lonza Group Increases Dividend

The firm also recently declared a dividend, which was paid on Friday, May 30th. Shareholders of record on Thursday, May 15th were given a dividend of $0.1054 per share. This is a boost from Lonza Group's previous dividend of $0.10. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a yield of 15.0%.

About Lonza Group

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.